A phase Ib trial to investigate exenatide (FT228) in patients with type 2 diabetes mellitus
Phase of Trial: Phase I
Latest Information Update: 08 Aug 2016
At a glance
- Drugs Exenatide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacodynamics; Pharmacokinetics
- 08 Aug 2016 Results published in a Flamel Technologies second quarter 2016 financial report.
- 08 Aug 2016 Status changed from planning to completed, according to a Flamel Technologies media release.
- 24 Dec 2015 New trial record